Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback